Real-life experience of ranibizumab for diabetic macular edema in Taiwan (Q89172339)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

1 April 2020

title

Real-life experience of ranibizumab for diabetic macular edema in Taiwan (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

1 April 2020

main subject

diabetic macular edema

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

1 April 2020

author name string

Yi-Ting Hsieh

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

1 April 2020

Yi-Jie Peng

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

1 April 2020

publication date

20 June 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

International Ophthalmology

1 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

1 April 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

1 April 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

1 April 2020

page(s)

1511-1522

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema.

1 April 2020

cites work

1 reference

12 December 2020

Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy

1 reference

12 December 2020

Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy

1 reference

12 December 2020

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

1 reference

12 December 2020

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

1 reference

12 December 2020

Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?

1 reference

12 December 2020

Global prevalence and major risk factors of diabetic retinopathy

1 reference

12 December 2020

Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.

1 reference

12 December 2020

Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab

1 reference

12 December 2020

Intravitreal ranibizumab for diabetic macular oedema: 1-year experiences in a clinical setting

1 reference

12 December 2020

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

1 reference

12 December 2020

Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

1 reference

12 December 2020

Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results

1 reference

12 December 2020

Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema

1 reference

12 December 2020

Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.

1 reference

12 December 2020

The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema.

1 reference

12 December 2020

Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.

1 reference

12 December 2020

Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study).

1 reference

12 December 2020

South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience

1 reference

12 December 2020

Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss

1 reference

12 December 2020

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema

1 reference

12 December 2020

Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema

1 reference

12 December 2020

Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial

1 reference

12 December 2020

The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis

1 reference

12 December 2020

Treatment of diabetic retinopathy: Recent advances and unresolved challenges

1 reference

12 December 2020

Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting

1 reference

12 December 2020

Short-Term Outcomes of Switching to Ranibizumab Therapy for Diabetic Macular Edema in Patients with Persistent Fluid After Bevacizumab Therapy

1 reference

12 December 2020

10.1007/S10792-018-0970-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29926364 AND SRC:MED&resulttype=core&format=json

1 April 2020

1 reference